AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.
Clin Pharmacol Ther. 2012 Jan;91(1):71-80. doi: 10.1038/clpt.2011.272. Epub 2011 Dec 7.
Vandetanib is a small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases that has demonstrated clinical benefits in patients with medullary thyroid cancer (MTC). By identifying patients who are in greatest need of therapy, the risks of vandetanib can be balanced against the potential benefits in patients for whom there had been no effective therapy until now. This review discusses the development of vandetanib in patients with MTC and the benefits and risks in this patient population.
凡德他尼是一种小分子血管内皮生长因子受体（VEGFR）、表皮生长因子受体（EGFR）和 RET 酪氨酸激酶抑制剂，已在甲状腺髓样癌（MTC）患者中显示出临床获益。通过确定最需要治疗的患者，可以权衡凡德他尼的风险与潜在获益，对于这些患者，凡德他尼是目前为止尚无有效治疗方法的情况下的一种选择。本文讨论了凡德他尼在 MTC 患者中的开发情况，以及该患者人群的获益和风险。
